Placebo News and Research

RSS

Oral contraceptive pills may increase binge eating in some women

A new study from Michigan State University found increases in binge eating when taking hormone pills in the form of oral contraceptives - but not in all women.

17 Jun 2026

Probiotics help reduce depressive symptoms in older adults

In a pilot clinical trial published in the Journal of the American Geriatrics Society that included older adults with depression receiving standard care, adding probiotic therapy produced modest but meaningful reductions in depressive and anxiety symptoms compared with adding a placebo.

17 Jun 2026

Tirzepatide activates calorie-burning brown fat to combat obesity

Tirzepatide doesn't just help people lose weight; it also activates brown adipose tissue, representing a major milestone in obesity research, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

16 Jun 2026

GLP-1s may improve testosterone levels and sperm quality in men with obesity

GLP‑1s do not harm male hormones or fertility after long-term use, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

15 Jun 2026

Short-chain oat fiber helps steady glucose and ease gut symptoms in pilot trial

A 14-day open-label pilot study in 63 healthy adults found that short-chain oat fiber was well tolerated at doses up to 20 g/day and was associated with improved gastrointestinal symptom scores.

14 Jun 2026

Testosterone benefits older men with T2D risk when combined with lifestyle changes

Testosterone treatment may improve body composition, glucose metabolism and sexual desire in some older men at high risk of type 2 diabetes (T2D), but the benefits require engagement in a lifestyle program, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Phase 3 study of in vivo CRISPR therapy for hereditary angioedema successfully completed

Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy.

13 Jun 2026

FDA approves new adjuvant treatment option for ccRCC patients with recurrence risk

The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.

12 Jun 2026

Parkinson's drug may ease anhedonia in treatment-resistant depression

For many people who suffer from depression, the condition is not just about feeling down, but also about a loss of motivation and difficulty finding pleasure in activities they used to enjoy.

12 Jun 2026

Study supports atropine drops for managing childhood short-sightedness

Low concentration atropine eye drops are a safe and effective treatment for short-sightedness (myopia) in UK children, although the effects are small, suggests a clinical trial published by The BMJ today.

11 Jun 2026

Trial finds prunes do not outperform calcium and vitamin D for male bone density

A one-year randomized trial found that daily prune supplementation did not improve total or lumbar spine bone mineral density in older men susceptible to, or with, osteopenia. Although some bone turnover biomarkers differed between prune and control groups, these changes did not translate into measurable bone density benefits beyond calcium and vitamin D3 supplementation.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Metformin reduces long COVID risk according to ACTIV-6 clinical trial

New findings from the ACTIV-6 randomized clinical trial provide important confirmation of prior clinical trial results that metformin, a widely available and inexpensive medication with an established safety record, reduced the risk of clinician-diagnosed long COVID when started during acute COVID-19 infection.

11 Jun 2026

Tranexamic acid reduces surgical transfusions without raising clot risks

A landmark clinical trial published in the prestigious New England Journal of Medicine found that tranexamic acid reduced transfusions across major surgeries without increasing the risk of dangerous blood clots.

10 Jun 2026

AI digital twins may improve bilingual aphasia rehabilitation

According to the National Aphasia Association, about 2 million U.S. citizens live with aphasia, but only two-thirds of Americans are aware of the condition, which is a communication disorder that often occurs after a stroke.

9 Jun 2026

Apitegromab helps tirzepatide users lose fat while preserving lean mass

A phase 2 trial found that apitegromab plus tirzepatide reduced lean body mass loss by 1.9 kg compared with tirzepatide plus placebo after 24 weeks, while overall weight loss remained similar.

9 Jun 2026

Obesity drug mazdutide reduces weight and waist size in major trial

Once-weekly 9 mg mazdutide produced clinically meaningful weight loss in Chinese adults with obesity, reducing body weight by 16.65% after 60 weeks versus 1.50% with placebo. The phase 3 GLORY-2 trial also found improvements in waist circumference, systolic blood pressure, and lipid markers, but gastrointestinal adverse events were common.

9 Jun 2026